ALK.CAR-T / Celldex - LARVOL DELTA

ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells (AACR 2024) - "These findings provide insights into the potential of ALK.CAR-T cells as a novel therapeutic strategy for neuroblastoma. A Phase I clinical trial to test ALK.CAR-T cells in combination with ALK TKIs in children with refractory/relapsed neuroblastoma is being implemented based on these results."

CAR T-Cell Therapy • IO biomarker • CNS Tumor • Neuroblastoma • Oncology • Solid Tumor • ALK

ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. (PubMed, Cancer Cell) - "Mechanistically, ALK inhibitors impair tumor growth and upregulate the expression of ALK, thereby facilitating the activity of ALK.CAR-T cells against neuroblastoma. Thus, while neither ALK inhibitors nor ALK.CAR-T cells will likely be sufficient as monotherapy in neuroblastoma with low ALK density, their combination specifically enhances therapeutic efficacy."

CAR T-Cell Therapy • IO biomarker • Journal • CNS Tumor • Hematological Disorders • Neuroblastoma • Oncology • Solid Tumor • ALK

ALK chimeric antigen receptor T cells cooperate with ALK inhibitors to target neuroblastoma cells with low target density (EACR 2023) - "These findings provide insights into the potential of ALK.CAR-T cells as a novel therapeutic strategy for neuroblastoma. A Phase I clinical trial to test ALK.CAR-T cells in combination with ALK TKIs in children with refractory/relapsed neuroblastoma is being implemented based on these results."

CAR T-Cell Therapy • IO biomarker • CNS Tumor • Hematological Disorders • Neuroblastoma • Neuroendocrine Tumor • Oncology • Solid Tumor • ALK